<p>伍德斯托克公司在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第三季度将其在再生元制药公司（NASDAQ:REGN - 免费报告）股票中的持股比例提高了 107.1%。该机构投资者在此期间额外购买了 8,589 股后，持有该生物制药公司 16,610 股股票。伍德斯托克公司在再生元制药的持股在最近一个季度末的价值为 9,339,000 美元。</p>
<ul>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
<p>其他一些机构投资者和对冲基金最近也对 REGN 的持仓进行了调整。Assenagon 资产管理公司在第三季度将其在再生元制药公司的持股比例提高了 12.9%。Assenagon 资产管理公司目前持有 477,810 股该生物制药公司的股票，价值为 268,658,000 美元，此前在上个季度额外购买了 54,485 股。Traphagen 投资顾问公司在第三季度将其在再生元制药公司的持仓提高了 2.7%。Traphagen 投资顾问公司目前持有 911 股该生物制药公司的股票，价值为 512,000 美元，此前在此期间额外购买了 24 股。Sicart Associates LLC 在第三季度获得了再生元制药公司的新头寸，价值约为 3,925,000 美元。联合私人银行 UBP SA 在第三季度将其在再生元制药公司的持仓提高了 10,440.0%。联合私人银行 UBP SA 目前持有 517 股该生物制药公司的股票，价值为 291,000 美元，此前在此期间额外购买了 522 股。最后，穆迪国家银行信托部门在第三季度将其在再生元制药公司的持股比例提高了 19.2%。穆迪国家银行信托部门目前持有 1,786 股该生物制药公司的股票，价值为 1,004,000 美元，此前在上个季度额外购买了 288 股。机构投资者和对冲基金持有该公司 83.31% 的股票。</p>
<h2>再生元制药的内部买卖</h2>
<p>在其他消息中，董事克里斯汀·阿·普恩于 10 月 29 日星期三出售了 6,500 股该股票。该股票的平均售价为 654.27 美元，总交易额为 4,252,755.00 美元。出售后，该董事在公司持有 2,352 股，价值约为 1,538,843.04 美元。这代表着他们持有的股票减少了 73.43%。该交易在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。此外，副总裁杰森·皮托夫斯基于 11 月 7 日星期五出售了 431 股再生元制药的股票。该股票的平均售价为 651.43 美元，总价值为 280,766.33 美元。交易完成后，副总裁直接持有 4,233 股公司的股票，价值为 2,757,503.19 美元。这代表着他们持有的股票减少了 9.24%。该交易的 SEC 文件提供了更多信息。目前 7.02% 的股票由公司内部人士持有。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>5 个医疗保健公司值得关注，因为行业轮动正在全面展开</li>
</ul>
<p>一些研究分析师最近对 REGN 股票发布了报告。Canaccord Genuity Group 将再生元制药公司的目标价格从 850.00 美元提高至 1,057.00 美元，并在 12 月 4 日的研究报告中给予该公司 “买入” 评级。华尔街 Zen 在 11 月 17 日的报告中将再生元制药公司的股票评级从 “持有” 上调至 “买入”。Truist Financial 在 11 月 24 日的研究报告中开始覆盖再生元制药公司。他们对该股票发布了 “买入” 评级和 798.00 美元的目标价。Weiss Ratings 在周一的研究报告中重申了对再生元制药公司的 “持有（c）” 评级。最后，雷蒙德·詹姆斯金融在 9 月 2 日的报告中将再生元制药公司评级提高至 “适度买入”。三位研究分析师对该股票给予了强烈买入评级，十五位给予了买入评级，八位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 779.45 美元。</p>
<p><strong>查看我们最新的再生元制药股票报告</strong></p>
<h2>再生元制药股票下跌 0.8%</h2>
<ul>
<li>大跌者：3 只接近一年低点的股票，可能在 2025 年大幅上涨</li>
</ul>
<p>REGN 股票在星期三开盘价为 746.36 美元。再生元制药公司过去 12 个月的最低价为 476.49 美元，最高价为 790.98 美元。该公司的速动比率为 3.33，流动比率为 4.06，债务股本比率为 0.09。该公司的市值为 784.4 亿美元，市盈率为 17.87，市盈增长比率为 2.15，贝塔值为 0.37。该公司的 50 日简单移动平均线为 671.04 美元，200 日简单移动平均线为 595.57 美元。</p>
<p>再生元制药（NASDAQ:REGN - 获取免费报告）最近于 10 月 28 日星期二公布了季度财报。该生物制药公司报告季度每股收益为 11.83 美元，超出分析师共识预期的 9.73 美元，超出幅度为 2.10 美元。再生元制药的股本回报率为 13.76%，净利润率为 32.13%。该公司在本季度的收入为 37.5 亿美元，而共识预期为 35.7 亿美元。去年同期，该公司每股收益为 12.46 美元。该公司的季度收入同比增长 0.9%。研究分析师预计再生元制药公司在本年度的每股收益将达到 35.92 美元。</p>
<h2>再生元制药分红公告</h2>
<p>该公司最近还披露了季度股息，该股息于 12 月 5 日（星期五）支付。11 月 20 日（星期四）登记在册的股东获得了每股 0.88 美元的股息。该股息的除息日为 11 月 20 日（星期四）。这相当于年化股息为 3.52 美元，收益率为 0.5%。再生元制药的派息比率目前为 8.43%。</p>
<h2>再生元制药公司简介</h2>
<p>（免费报告）</p>
<p>再生元制药公司（Regeneron Pharmaceuticals, Inc）在全球范围内发现、发明、开发、生产和商业化用于治疗各种疾病的药物。公司的产品包括用于治疗湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的 EYLEA 注射剂；近视性脉络膜新生血管；糖尿病视网膜病；新生血管性青光眼；以及早产儿视网膜病。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比再生元制药更好的股票</li>
<li>如何寻找被低估的股票</li>
<li>三只科技股下跌超过 60%——哪一只值得购买？</li>
<li>纳斯达克是什么？完整概述及历史</li>
<li>25 年后，思科终于从互联网泡沫崩溃中恢复</li>
<li>股票中的死亡交叉是什么？</li>
<li>AI 芯片离不开这两家被低估的科技巨头</li>
</ul>
<p><strong>想看看其他对 REGN 感兴趣的对冲基金持有哪些股票？</strong> 请访问 HoldingsChannel.com，获取再生元制药公司（NASDAQ:REGN - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在再生元制药吗？</h2>
<p>在考虑再生元制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而再生元制药并不在名单上。</p>
<p>尽管再生元制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

再生元制药

<p>Woodstock Corp 在第三季度将其在再生元制药的股份增加了 107.1%，目前持有 16,610 股，价值 9,339,000 美元。其他投资者也调整了他们在 REGN 的持仓。内部人士的销售包括董事 Christine A. Poon 和副总裁 Jason Pitofsky。分析师发布了新的价格目标，普遍评级为 “适度买入”，平均价格目标为 779.45 美元。REGN 股票开盘价为 746.36 美元，12 个月低点为 476.49 美元，高点为 790.98 美元</p>

<p>Woodstock Corp raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 107.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,610 shares of the biopharmaceutical company's stock after buying an additional 8,589 shares during the period. Woodstock Corp's holdings in Regeneron Pharmaceuticals were worth $9,339,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>伍德斯托克公司在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第三季度将其在再生元制药公司（NASDAQ:REGN - 免费报告）股票中的持股比例提高了 107.1%。该机构投资者在此期间额外购买了 8,589 股后，持有该生物制药公司 16,610 股股票。伍德斯托克公司在再生元制药的持股在最近一个季度末的价值为 9,339,000 美元。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently made changes to their positions in REGN. Assenagon Asset Management S.A. raised its stake in shares of Regeneron Pharmaceuticals by 12.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 477,810 shares of the biopharmaceutical company's stock valued at $268,658,000 after acquiring an additional 54,485 shares in the last quarter. Traphagen Investment Advisors LLC boosted its position in Regeneron Pharmaceuticals by 2.7% during the third quarter. Traphagen Investment Advisors LLC now owns 911 shares of the biopharmaceutical company's stock worth $512,000 after purchasing an additional 24 shares during the period. Sicart Associates LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $3,925,000. Union Bancaire Privee UBP SA raised its position in shares of Regeneron Pharmaceuticals by 10,440.0% in the third quarter. Union Bancaire Privee UBP SA now owns 517 shares of the biopharmaceutical company's stock valued at $291,000 after purchasing an additional 522 shares during the period. Finally, Moody National Bank Trust Division lifted its stake in shares of Regeneron Pharmaceuticals by 19.2% in the third quarter. Moody National Bank Trust Division now owns 1,786 shares of the biopharmaceutical company's stock worth $1,004,000 after buying an additional 288 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也对 REGN 的持仓进行了调整。Assenagon 资产管理公司在第三季度将其在再生元制药公司的持股比例提高了 12.9%。Assenagon 资产管理公司目前持有 477,810 股该生物制药公司的股票，价值为 268,658,000 美元，此前在上个季度额外购买了 54,485 股。Traphagen 投资顾问公司在第三季度将其在再生元制药公司的持仓提高了 2.7%。Traphagen 投资顾问公司目前持有 911 股该生物制药公司的股票，价值为 512,000 美元，此前在此期间额外购买了 24 股。Sicart Associates LLC 在第三季度获得了再生元制药公司的新头寸，价值约为 3,925,000 美元。联合私人银行 UBP SA 在第三季度将其在再生元制药公司的持仓提高了 10,440.0%。联合私人银行 UBP SA 目前持有 517 股该生物制药公司的股票，价值为 291,000 美元，此前在此期间额外购买了 522 股。最后，穆迪国家银行信托部门在第三季度将其在再生元制药公司的持股比例提高了 19.2%。穆迪国家银行信托部门目前持有 1,786 股该生物制药公司的股票，价值为 1,004,000 美元，此前在上个季度额外购买了 288 股。机构投资者和对冲基金持有该公司 83.31% 的股票。</p>
</div><h2>Insider Buying and Selling at Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>再生元制药的内部买卖</h2>
</div><p>In other news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares of the company's stock, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.02% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，董事克里斯汀·阿·普恩于 10 月 29 日星期三出售了 6,500 股该股票。该股票的平均售价为 654.27 美元，总交易额为 4,252,755.00 美元。出售后，该董事在公司持有 2,352 股，价值约为 1,538,843.04 美元。这代表着他们持有的股票减少了 73.43%。该交易在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。此外，副总裁杰森·皮托夫斯基于 11 月 7 日星期五出售了 431 股再生元制药的股票。该股票的平均售价为 651.43 美元，总价值为 280,766.33 美元。交易完成后，副总裁直接持有 4,233 股公司的股票，价值为 2,757,503.19 美元。这代表着他们持有的股票减少了 9.24%。该交易的 SEC 文件提供了更多信息。目前 7.02% 的股票由公司内部人士持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 个医疗保健公司值得关注，因为行业轮动正在全面展开</li>
</ul>
</div><p>A number of research analysts recently issued reports on REGN shares. Canaccord Genuity Group raised their target price on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, December 4th. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Monday, November 17th. Truist Financial assumed coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They issued a &#34;buy&#34; rating and a $798.00 price objective on the stock. Weiss Ratings restated a &#34;hold (c)&#34; rating on shares of Regeneron Pharmaceuticals in a research note on Monday. Finally, Raymond James Financial raised Regeneron Pharmaceuticals to a &#34;moderate buy&#34; rating in a report on Tuesday, September 2nd. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $779.45.</p>
<div class="lb-trans"><p>一些研究分析师最近对 REGN 股票发布了报告。Canaccord Genuity Group 将再生元制药公司的目标价格从 850.00 美元提高至 1,057.00 美元，并在 12 月 4 日的研究报告中给予该公司 “买入” 评级。华尔街 Zen 在 11 月 17 日的报告中将再生元制药公司的股票评级从 “持有” 上调至 “买入”。Truist Financial 在 11 月 24 日的研究报告中开始覆盖再生元制药公司。他们对该股票发布了 “买入” 评级和 798.00 美元的目标价。Weiss Ratings 在周一的研究报告中重申了对再生元制药公司的 “持有（c）” 评级。最后，雷蒙德·詹姆斯金融在 9 月 2 日的报告中将再生元制药公司评级提高至 “适度买入”。三位研究分析师对该股票给予了强烈买入评级，十五位给予了买入评级，八位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 779.45 美元。</p>
</div><p><strong>View Our Latest Stock Report on Regeneron Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的再生元制药股票报告</strong></p>
</div><h2>Regeneron Pharmaceuticals Stock Down 0.8%</h2>
<div class="lb-trans"><h2>再生元制药股票下跌 0.8%</h2>
</div><ul>
<li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>大跌者：3 只接近一年低点的股票，可能在 2025 年大幅上涨</li>
</ul>
</div><p>REGN stock opened at $746.36 on Wednesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $790.98. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The company has a market cap of $78.44 billion, a PE ratio of 17.87, a price-to-earnings-growth ratio of 2.15 and a beta of 0.37. The business's 50-day simple moving average is $671.04 and its 200 day simple moving average is $595.57.</p>
<div class="lb-trans"><p>REGN 股票在星期三开盘价为 746.36 美元。再生元制药公司过去 12 个月的最低价为 476.49 美元，最高价为 790.98 美元。该公司的速动比率为 3.33，流动比率为 4.06，债务股本比率为 0.09。该公司的市值为 784.4 亿美元，市盈率为 17.87，市盈增长比率为 2.15，贝塔值为 0.37。该公司的 50 日简单移动平均线为 671.04 美元，200 日简单移动平均线为 595.57 美元。</p>
</div><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts' consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter last year, the company earned $12.46 EPS. The company's quarterly revenue was up .9% on a year-over-year basis. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.</p>
<div class="lb-trans"><p>再生元制药（NASDAQ:REGN - 获取免费报告）最近于 10 月 28 日星期二公布了季度财报。该生物制药公司报告季度每股收益为 11.83 美元，超出分析师共识预期的 9.73 美元，超出幅度为 2.10 美元。再生元制药的股本回报率为 13.76%，净利润率为 32.13%。该公司在本季度的收入为 37.5 亿美元，而共识预期为 35.7 亿美元。去年同期，该公司每股收益为 12.46 美元。该公司的季度收入同比增长 0.9%。研究分析师预计再生元制药公司在本年度的每股收益将达到 35.92 美元。</p>
</div><h2>Regeneron Pharmaceuticals Dividend Announcement</h2>
<div class="lb-trans"><h2>再生元制药分红公告</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is currently 8.43%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度股息，该股息于 12 月 5 日（星期五）支付。11 月 20 日（星期四）登记在册的股东获得了每股 0.88 美元的股息。该股息的除息日为 11 月 20 日（星期四）。这相当于年化股息为 3.52 美元，收益率为 0.5%。再生元制药的派息比率目前为 8.43%。</p>
</div><h2>Regeneron Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>再生元制药公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.</p>
<div class="lb-trans"><p>再生元制药公司（Regeneron Pharmaceuticals, Inc）在全球范围内发现、发明、开发、生产和商业化用于治疗各种疾病的药物。公司的产品包括用于治疗湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的 EYLEA 注射剂；近视性脉络膜新生血管；糖尿病视网膜病；新生血管性青光眼；以及早产儿视网膜病。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Regeneron Pharmaceuticals</li>
<li>How to Find Undervalued Stocks</li>
<li>3 Tech Stocks Down Over 60%—Which One Is Worth Buying?</li>
<li>What is the Nasdaq? Complete Overview with History</li>
<li>25 Years Later, Cisco Finally Recovers From the Dot-Com Crash</li>
<li>What is a Death Cross in Stocks?</li>
<li>AI Chips Can’t Exist Without These 2 Underrated Tech Giants</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比再生元制药更好的股票</li>
<li>如何寻找被低估的股票</li>
<li>三只科技股下跌超过 60%——哪一只值得购买？</li>
<li>纳斯达克是什么？完整概述及历史</li>
<li>25 年后，思科终于从互联网泡沫崩溃中恢复</li>
<li>股票中的死亡交叉是什么？</li>
<li>AI 芯片离不开这两家被低估的科技巨头</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding REGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 REGN 感兴趣的对冲基金持有哪些股票？</strong> 请访问 HoldingsChannel.com，获取再生元制药公司（NASDAQ:REGN - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=REGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在再生元制药吗？</h2>
</div><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑再生元制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而再生元制药并不在名单上。</p>
</div><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管再生元制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

伍德斯托克公司收购了再生元制药公司 8,589 股股票